8V8 logo

Genetic Analysis DB:8V8 Stock Report

Last Price

€0.025

Market Cap

€2.0m

7D

-11.3%

1Y

-51.0%

Updated

22 Dec, 2024

Data

Company Financials

8V8 Stock Overview

A science-based diagnostic company, develops diagnostic solutions for human microbiome market. More details

8V8 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Genetic Analysis AS Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genetic Analysis
Historical stock prices
Current Share PriceNOK 0.025
52 Week HighNOK 0.12
52 Week LowNOK 0.017
Beta1.82
1 Month Change45.35%
3 Month Change-49.60%
1 Year Change-50.98%
3 Year Change-95.86%
5 Year Changen/a
Change since IPO-97.55%

Recent News & Updates

Recent updates

Shareholder Returns

8V8DE BiotechsDE Market
7D-11.3%-3.5%-2.0%
1Y-51.0%-14.7%6.9%

Return vs Industry: 8V8 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 8V8 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 8V8's price volatile compared to industry and market?
8V8 volatility
8V8 Average Weekly Movement25.5%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 8V8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8V8's weekly volatility has decreased from 45% to 25% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200821Ronny Hermansenwww.genetic-analysis.com

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market. It offers GA-map Dysbiosis Test Lx, a molecular assay for profiling the gut microbiota to identify and characterize dysbiosis for treating patients with Irritable Bowel Syndrome, Inflammatory Bowel Disease, diabetes type 2, gut disorder, lifestyle diseases, and leaky-gut syndrome; GA-map COVID-19 Fecal Test Kit, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples; GA-map Dysbiosis Test reagent kit, a CE-IVD documented test, which is a software that performs QC on the run file, calculates the dysbiosis index score and abundance table, and converts sample result into reports; and GA-map Covid fecal test reagent kit, a CE-IVD documented test to detect SARS-CoV-2 in fecal samples. The company was founded in 2008 and is headquartered in Oslo, Norway.

Genetic Analysis AS Fundamentals Summary

How do Genetic Analysis's earnings and revenue compare to its market cap?
8V8 fundamental statistics
Market cap€2.05m
Earnings (TTM)-€1.74m
Revenue (TTM)€1.67m

1.2x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8V8 income statement (TTM)
RevenueNOK 19.71m
Cost of RevenueNOK 3.68m
Gross ProfitNOK 16.03m
Other ExpensesNOK 36.55m
Earnings-NOK 20.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin81.35%
Net Profit Margin-104.06%
Debt/Equity Ratio20.5%

How did 8V8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genetic Analysis AS is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gediminas RuginisNorne Securities AS